摘要
内脏利什曼病(VL)又被称为黑热病,是人体被利什曼原虫感染所致的播散性原虫病。VL患者的临床表现包括长期发热,肝、脾大,全血细胞减少及进行性贫血与消瘦等。我国治疗VL的临床药物以5价锑剂为主。目前临床治疗VL可供选择的药物种类少。笔者拟就VL患者药物治疗方案的最新研究进展进行阐述,旨在为该病患者的临床治疗提供参考。
Visceral Leishmaniasis(VL),also known as Kala-Azar,is a disseminated protozoal infection disease caused by Leishmania.Clinical manifestations of VL patients include chronic fever,hepatosplenomegaly,pancytopenia,progressive anemia and emaciation,etc..In China,penta-valent antimony is the main treatment option for VL patients.At present,there are a few kinds of medicine available for clinical treatment of VL.This article focuses on review latest research progresses of clinical treatment for VL patients so as to provide reference for physicians.
作者
袁传杰
杨雪
朱渝
Chuanjie Yuan;Xue Yang;Yu Zhu(Department of Pediatrics,Key Laboratory of Birth Defects and Related Diseases of Women and Children(Sichuan University),Ministry of Education,West China Second University Hospital,Sichuan University,Chengdu 610041,Sichuan Province,China)
出处
《中华妇幼临床医学杂志（电子版）》
CAS
2022年第4期387-392,共6页
Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition)
基金
四川省科技厅课题(2022YFS0243)。
关键词
利什曼病
内脏
临床方案
5价锑剂
两性霉素B
巴龙霉素
米替福新
喷他脒
儿童
Leishmaniasis
visceral
Clinical protocols
Penta-valent antimonials
Amphotericin B
Paromomycin
Miltefosine
Pentamidine
Child
